Top Ten Pharmaceutical Events In 2007
This article was originally published in PharmAsia News
The 2007 top ten multinational pharmaceutical business events in China have been shortlisted as follows: 1) Eli Lilly & Co. put $100 million in Asian risk investment funds in China; 2) Roche established a drug R&D center in China; 3) Johnson & Johnson (China) mounted a buyback of Xian-Janssen shares; 4) Wyeth injected $58.5 million to expand its drug business; 5) Alliance BMP and Guangzhou Pharmaceutical Corp. established a joint venture; 6) GlaxoSmithKline's cervical cancer vaccine Cervarix launched in Macau; 7) Bayer acquired Topsun's OTC cough and cold medicine business; 8) Novartis boosted its OTC drug business; 9) Xian-Janssen broke ties with distributor Nanjing Pharmaceutical; 10) retail price dispute between TSKF and local drugstores. (Click here for more)
You may also be interested in...
ODAC's 17-18 June discussion of pediatric development plans for four investigational oncology agents will serve as a trial run of the technology platform and logistics for any future application-specific virtual advisory committee meeting, but without the stress associated with a pending application and a user fee deadline.
Vibostolimab is less advanced than Roche’s competing tiragolumab, but Merck thinks the combo of its anti-TIGIT and Keytruda will offer a better therapeutic profile.
Ambitious efforts to make the EU more resilient to future challenges, such as health threats, drug supply problems, scientific advances and growing medicine costs, have taken a step forward with the publication of a roadmap for a wide-ranging Pharmaceutical Strategy to be adopted by the European Commission later in the year.